Niktimvo (Axatilimab-Csfr) Patent Expiration, LOE Window & CMS Spending

Niktimvo (Axatilimab-Csfr) by Incyte: Biologic BLA (PHS Act / Purple Book), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $11,968 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIncyte
FDA Application & PathwayB761411 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (PHS Act / Purple Book)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($11,968 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.